Table 3. Treatment exposure.
Exposure | Lapatinib + capecitabine (n=49) | T-DM1 (n=151) | ||
---|---|---|---|---|
Lapatinib | Capecitabine | All-grade | ||
Cycles received, n (%) | ||||
≤6 | 15 (30.6) | 15 (30.6) | 63 (41.7) | |
7–12 | 21 (42.9) | 21 (42.9) | 53 (35.1) | |
13–18 | 12 (24.5) | 12 (24.5) | 29 (19.2) | |
19–24 | 1 (2.0) | 1 (2.0) | 5 (3.3) | |
>24 | 0 | 0 | 1 (0.7) | |
Median treatment duration, months [range] | 6.1 [1–14] | 6.4 [1–14] | 5.5 [0–17] |
T-DM1, trastuzumab emtansine.